Aviso Financial Inc. Boosts Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Aviso Financial Inc. increased its stake in Thermo Fisher Scientific by 7.9% during the first quarter, acquiring an additional 7,483 shares, now totaling 102,592 shares valued at approximately $51 million.
• Recent insider transactions include the sale of shares by both the EVP and CEO, with Gianluca Pettiti selling 400 shares and CEO Marc Casper selling 10,000 shares, indicating a decrease in their ownership in the company.
• Analysts have mixed opinions on Thermo Fisher Scientific, with recent reports leading to target price adjustments ranging from $480 to $651, while the stock has an average rating of "Moderate Buy" with a consensus target price of $593.

Aviso Financial Inc. increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.9% in the first quarter, according to its most recent filing with the SEC. The fund owned 102,592 shares of the medical research company's stock after acquiring an additional 7,483 shares during the period. Thermo Fisher Scientific comprises 2.5% of Aviso Financial Inc.'s portfolio, making the stock its 15th biggest position. Aviso Financial Inc.'s holdings in Thermo Fisher Scientific were worth $51,050,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of TMO. Brighton Jones LLC lifted its stake in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares during the last quarter. Bank Pictet & Cie Europe AG lifted its stake in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock worth $79,677,000 after acquiring an additional 461 shares during the last quarter. First Trust Advisors LP lifted its stake in shares of Thermo Fisher Scientific by 17.4% during the 4th quarter. First Trust Advisors LP now owns 36,602 shares of the medical research company's stock worth $19,042,000 after acquiring an additional 5,438 shares during the last quarter. Finally, Curi RMB Capital LLC lifted its stake in shares of Thermo Fisher Scientific by 2.4% during the 4th quarter. Curi RMB Capital LLC now owns 17,901 shares of the medical research company's stock worth $9,313,000 after acquiring an additional 418 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Down 2.3%

Shares of NYSE:TMO traded down $11.3820 on Thursday, reaching $483.4280. The company had a trading volume of 1,360,628 shares, compared to its average volume of 2,488,796. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The firm's 50 day simple moving average is $439.69 and its 200-day simple moving average is $458.78. The firm has a market capitalization of $182.55 billion, a PE ratio of 27.96, a PEG ratio of 2.66 and a beta of 0.74. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the business posted $5.37 EPS. The business's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is 9.95%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TMO. Barclays lifted their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research report on Friday, July 11th. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Finally, Robert W. Baird lifted their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $593.00.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $52,037,916.68. The trade was a 7.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,896 shares of company stock worth $8,593,838. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.